Have a personal or library account? Click to login

OLAPARIB: A promising PARP Inhibitor for the treatment of ovarian cancer

Forum of Clinical Oncology
Volume 6 (2015): Issue 3 (September 2015)
By:
Open Access
|Dec 2015

References

  1. [1] Fong PC, Yap TA, Boss DS, Carden CP, Mergui- Roelvink M, Gourley C, De Greve J, Lubinski J, Shanley S, Messiou C, A’Hern R, Tutt A, Ashworth A, Stone J, Carmichael J, Schellens JH, de Bono JS, Kaye SB. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol. 2010 May 20;28(15):2512-9. doi: 10.1200/ JCO.2009.26.9589. Epub 2010 Apr 20.10.1200/JCO.2009.26.9589
    Search in Google Scholar
  2. [2] Fong PC, Yap TA, Boss DS, Carden CP, Mergui- Roelvink M, Gourley C, De Greve J, Lubinski J, Shanley S, Messiou C, A’Hern R, Tutt A, Ashworth A, Stone J, Carmichael J, Schellens JH, de Bono JS, Kaye SB. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol. 2010 May 20;28(15):2512-9. doi: 10.1200/ JCO.2009.26.9589. Epub 2010 Apr 20.10.1200/JCO.2009.26.9589
    Search in Google Scholar
  3. [3] Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, Bell-McGuinn KM, Scott C, Weitzel JN, Oaknin A, Loman N, Lu K, Schmutzler RK, Matulonis U, Wickens M, Tutt A. Oral poly(ADPribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet. 2010 Jul 24;376(9737):245-51. doi: 10.1016/ S0140-6736(10)60893-8. Epub 2010 Jul 6.10.1016/S0140-6736(10)60893-8
    Search in Google Scholar
  4. [4] Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, Tonkin K, Hirte H, Huntsman D, Clemons M, Gilks B, Yerushalmi R, Macpherson E, Carmichael J, Oza A. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol. 2011 Sep;12(9):852-61. doi: 10.1016/S1470-2045(11)70214-5. Epub 2011 Aug 19.10.1016/S1470-2045(11)70214-5
    Search in Google Scholar
  5. [5] Kaufman B1, Shapira-Frommer R1, Schmutzler RK1, Audeh MW1, Friedlander M1, Balmaña J1, Mitchell G1, Fried G1, Stemmer SM1, Hubert A1, Rosengarten O1, Steiner M1, Loman N1, Bowen K1, Fielding A1, Domchek SM2. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol. 2015 Jan 20;33(3):244-50. doi: 10.1200/JCO.2014.56.2728. Epub 2014 Nov 3.10.1200/JCO.2014.56.2728
    Search in Google Scholar
  6. [6] Kaye SB, Lubinski J, Matulonis U, Ang JE, Gourley C, Karlan BY, Amnon A, Bell-McGuinn KM, Chen LM, Friedlander M, Safra T, Vergote I, Wickens M, Lowe ES, Carmichael J, Kaufman B. Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J Clin Oncol. 2012 Feb 1;30(4):372-9. doi: 10.1200/ JCO.2011.36.9215. Epub 2011 Dec 27.10.1200/JCO.2011.36.9215
    Search in Google Scholar
  7. [7] Ledermann J1, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira- Frommer R, Safra T, Matei D, Macpherson E, Watkins C, Carmichael J, Matulonis U. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012 Apr 12;366(15):1382-92. doi: 10.1056/NEJMoa1105535. Epub 2012 Mar 27.10.1056/NEJMoa1105535
    Search in Google Scholar
  8. [8] Oza AM, Cibula D, Benzaquen AO, Poole C, Mathijssen RH, Sonke GS, Colombo N, Špaček J, Vuylsteke P, Hirte H, Mahner S, Plante M, Schmalfeldt B, Mackay H, Rowbottom J, Lowe ES, Dougherty B, Barrett JC, Friedlander M. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. Lancet Oncol. 2015 Jan;16(1):87-97. doi: 10.1016/S1470-2045(14)71135-0. Epub 2014 Dec 4.10.1016/S1470-2045(14)71135-0
    Search in Google Scholar
  9. [9] Ledermann J1, Harter P2, Gourley C3, Friedlander M4, Vergote I5, Rustin G6, Scott CL7, Meier W8, Shapira-Frommer R9, Safra T10, Matei D11, Fielding A12, Spencer S12, Dougherty B13, Orr M12, Hodgson D12, Barrett JC13, Matulonis U14. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 2014 Jul;15(8):852-61. doi: 10.1016/S1470-2045(14)70228-1. Epub 2014 May 31.10.1016/S1470-2045(14)70228-1
    Search in Google Scholar
  10. [10] Ledermann J1, Harter P2, Gourley C3, Friedlander M4, Vergote I5, Rustin G6, Scott CL7, Meier W8, Shapira-Frommer R9, Safra T10, Matei D11, Fielding A12, Spencer S12, Dougherty B13, Orr M12, Hodgson D12, Barrett JC13, Matulonis U14. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 2014 Jul;15(8):852-61. doi: 10.1016/S1470-2045(14)70228-1. Epub 2014 May 31.10.1016/S1470-2045(14)70228-1
    Search in Google Scholar
  11. [11] Jemal A1, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics.CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90. doi: 10.3322/ caac.20107. Epub2011 Feb 4.10.3322/caac.20107
    Search in Google Scholar
  12. [12] Fung-Kee-Fung M, Oliver T, Elit L, Oza A, Hirte HW, Bryson P. Optimal chemotherapy treatment for women with recurrent ovarian cancer. Curr Oncol. 2007 Oct;14(5):195-208.10.3747/co.2007.148
    Search in Google Scholar
  13. [13] Parmar MK, Ledermann JA, Colombo N, du Bois A, Delaloye JF, Kristensen GB, Wheeler S, Swart AM, Qian W, Torri V, Floriani I, Jayson G, Lamont A, Tropé C. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/ AGO-OVAR-2.2 trial.; ICON and AGO Collaborators. Lancet. 2003 Jun 21;361(9375):2099-106.10.1016/S0140-6736(03)13718-X
    Search in Google Scholar
  14. [14] Moynahan ME1, Chiu JW, Koller BH, Jasin M.Brca1 controls homology-directed DNA repair. Mol Cell. 1999 Oct;4(4):511-8.10.1016/S1097-2765(00)80202-6
    Search in Google Scholar
  15. [15] Moynahan ME, Pierce AJ, Jasin M. BRCA2 is required for homology-directed repair of chromosomal breaks. Mol Cell. 2001 Feb;7(2):263-72.10.1016/S1097-2765(01)00174-5
    Search in Google Scholar
  16. [16] Konstantinopoulos PA1, Spentzos D, Karlan BY, Taniguchi T, Fountzilas E, Francoeur N, Levine DA, Cannistra SA. Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. J Clin Oncol. 2010 Aug 1;28(22):3555-61. doi: 10.1200/JCO.2009.27.5719. Epub 2010 Jun 14.10.1200/JCO.2009.27.5719291731120547991
    Search in Google Scholar
  17. [17] Liu JF, Tolaney SM, Birrer M, Fleming GF, Buss MK, Dahlberg SE, Lee H, Whalen C, Tyburski K, Winer E, Ivy P, Matulonis UA.A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer. Eur J Cancer. 2013 Sep;49(14):2972-8. doi: 10.1016/j. ejca.2013.05.020. Epub 2013 Jun 27.
    Search in Google Scholar
  18. [18] Zhang S, Royer R, Li S, McLaughlin JR, Rosen B, Risch HA, Fan I, Bradley L, Shaw PA, Narod SA. Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer. Gynecol Oncol. 2011 May 1;121(2):353-7. doi: 10.1016/j.ygyno.2011.01.020. Epub 2011 Feb 15.10.1016/j.ygyno.2011.01.02021324516
    Search in Google Scholar
  19. [19] Camille C Gunderson , Kathleen N Moore Olaparib: an oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian cancer. Future Oncology, Vol. 11, No. 5, Pages 747-757.10.2217/fon.14.31325757679
    Search in Google Scholar
  20. [20] Ang JE, Gourley C, Powell CB, High H, Shapira- Frommer R, Castonguay V, De Greve J, Atkinson T, Yap TA, Sandhu S, Banerjee S, Chen LM, Friedlander ML, Kaufman B, Oza AM, Matulonis U, Barber LJ, Kozarewa I, Fenwick K, Assiotis I, Campbell J, Chen L, de Bono JS, Gore ME, Lord CJ, Ashworth A, Kaye SB. Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multiinstitutional study. Clin Cancer Res. 2013 Oct 1;19(19):5485-93. doi: 10.1158/1078-0432.CCR-13-1262. Epub 2013 Aug 6. 10.1158/1078-0432.CCR-13-126223922302
    Search in Google Scholar
DOI: https://doi.org/10.1515/fco-2015-0014 | Journal eISSN: 1792-362X | Journal ISSN: 1792-345X
Journal RSS Feed
Language: English
Page range: 1 - 7
Submitted on: Sep 18, 2015
Accepted on: Sep 30, 2015
Published on: Dec 17, 2015
Published by: Helenic Society of Medical Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 2 times per year
Keywords:
PARP-inhibitors,
Olaparib,
Ovarian Cancer
Related subjects:
Medicine,
Clinical medicine,
Internal medicine,
Haematology, oncology

© 2015 Nikolaos Soupos, Konstantinos Laschos, Evangelos Bournakis, Euthymios Kostouros, Gerasimos Aravantinos, published by Helenic Society of Medical Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Volume 6 (2015): Issue 3 (September 2015)Next article